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clinical studies are warranted to optimize the management 
of vasculitis-associated PRES.
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Introduction
Churg–Strauss syndrome, recently renamed eosinophilic 
granulomatosis with polyangiitis (EGPA), is a small-
sized vessel systemic necrotizing vasculitis that was first 
described in the early 1950s. It belongs to the family of 
antineutrophil cytoplasmic antibody (ANCA)-associated 
vasculitides. It is a rare disease, with an annual incidence 
ranging between 0.5 and 6.8 per million inhabitants and a 
prevalence of 10.7–14 per million inhabitants [1], with a 
mean age at the onset around 50 years and no sex prepon-
derance. The most typical clinical presentation of EGPA 
is the appearance of vasculitic manifestations in a patient 
with known allergic rhinitis, nasal and sinus polyposis, and 
late-onset asthma (almost constant, and usually preexisting 
for 5–10 years). General symptoms (fever or weight loss), 
mononeuritis multiplex, and/or necrotic cutaneous purpura 
are the most frequent manifestations at disease onset, in 
combination with elevated blood eosinophilia. The detec-
tion of ANCA, namely P-ANCA (with perinuclear labe-
ling pattern in indirect immunofluorescence), with anti-
myeloperoxidase (anti-MPO) specificity in enzyme-linked 
immunosorbent assay, strongly supports the diagnosis, 
but they are present only in 35–40 % of patients [2]. The 
involvement of central nervous system is pretty rare. PRES 
(posterior reversible encephalopathy syndrome) is a clini-
cal and radiological entity described for the first time by 
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cal vasogenic edema predominantly in the white matter of 
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diagnosis of EGPA with a concise review of the literature. 
The exact cause of this syndrome is unknown. It has been 
related to eclampsia, drug-induced hypertension, renal 
insufficiency and also to rheumatologic diseases. Endothe-
lial injury, hypertension and immunosuppressive medi-
cations can compromise the regulation of cerebral blood 
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with symptoms of PRES represent a challenge to treatment 
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inflammatory process might be implicated, judicious use of 
these agents along with tight control of blood pressure and 
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Hinchey et al. [4] and characterized by MRI findings of 
reversible subcortical vasogenic edema predominantly in 
the white matter of posterior cerebral lobes. The authors 
named this condition “Reversible Posterior Leukoencepha-
lopathy Syndrome.” However, some authors considered this 
term as misleading, as they observed also the involvement 
of the gray matter, hence the definition “posterior revers-
ible encephalopathy syndrome” (PRES) was coined. Main 
clinical features are seizures, headache, visual disturbances 
and altered mental status. The cause of this syndrome is 
unknown. Nevertheless it has been etiologically related to 
hypertension (there is in fact a strong association with pre-
eclampsia), end-stage renal disease, immunosuppressive 
drugs (mainly cyclosporine and tacrolimus), and rheumato-
logic diseases, mainly SLE, and, less frequently, Takayasu 
arteritis, systemic sclerosis, polyarteritis nodosa, granulo-
matosis with polyangiitis, thrombotic thrombocytopenic 
purpura. Endothelial disfunction and altered cerebral vas-
oregulation are implicated in the pathophysiology. There 
are few case reports describing the concurrence of PRES 
with ANCA-associated vasculitides. Here we describe a 
case of PRES in a patient with a diagnosis (according to 
the ACR criteria) of eosinophilic granulomatosis with poly-
angiitis (EGPA), along with a concise review of the litera-
ture. To our knowledge, this is the first documented case of 
PRES in a patient with a definite diagnosis of EGPA.
Materials and methods
The review was based on a literature search for articles 
concerning PRES in ANCA-associated vasculitides, pub-
lished from 2001 through December 2014. No cases have 
been published before 2001. We used the Medline database 
(PubMed, National Library of Medicine, Bethesda, MD; 
keywords: posterior reversible encephalopathy, ANCA, 
vasculitis, connective tissue diseases). The reference lists of 
all articles were scanned for references not identified in the 
initial research. Eight cases of PRES along with ANCA-
associated vasculitides were included in this study, so that 
with our case, we reviewed a total of 9 cases.
Case
A 40-year-old Caucasian man presented with sudden loss 
of strength in the four limbs and skin lesions of the lower 
limbs. His medical history was remarkable for asthma 
and nasal polyposis. He firstly developed weakness of the 
right hand and, 2 weeks later, numbness and weakness of 
the lower limbs along with the onset of vesiculous bul-
lous skin lesions on both legs. At the admission, the patient 
was conscious, oriented, and had no signs of cognitive 
impairment. His physical examination was unremarkable 
except for numbness and loss of strength in the four limbs 
and vesiculous bullous skin lesions of the lower limbs. 
The patient’s blood pressure was 140/90 mmHg. His heart 
rate was 72 bpm. Routine blood tests showed leukocyto-
sis with hypereosinophilia (WBC 21,480/mcl with a ref-
erence range of 4000–1000 cells/µl, Eos 11,190/µl with 
a reference range of 50–500/µl). C-reactive protein was 
9,94 mg/dl (normal values up to 0.5 mg/dl), erythrocyte 
sedimentation rate (ESR) was 61 mm/h (normal values up 
to 15 mm/h), and p-ANCA were positive at high titer (100 
UA/ml). Blood urea nitrose was normal and his serum cre-
atinine was 0.7 mg/dL. A brain MRI and MRI of the spine 
performed before being admitted to our department showed 
no significant abnormalities. A chest X-ray showed pul-
monary infiltrates in the right lung. An electroneurography 
showed sensori-motor axonal neuropathy with asymmetric 
distribution (mononeuritis multiplex), compatible with vas-
culitis. A skin biopsy and muscle biopsy showed vasculitis 
with extravascular eosinophils. Eosinophilic granulomato-
sis with polyangiitis was diagnosed as the patient fulfilled 5 
of the 6 criteria by the American College of Rheumatology. 
Serum creatinine was normal, and he had no renal damage. 
Blood pressure was in normal range at the exordium. The 
patient was treated with intravenous methylprednisolone (1 
gram per day for 3 days), followed by prednisone 1 mg/kg 
with subsequent tapering. A week after starting treatment, 
he presented generalized tonic–clonic seizures, headache, 
and transient lack of vision. His blood pressure at the onset 
of crisis was 170/100 mmHg. A brain MRI was performed, 
and T2-weighted image showed bilateral high-intensity 
areas in the white matter of the occipital and parietal lobes. 
These findings (Fig. 1) were suggestive of PRES (poste-
rior reversible encephalopathy syndrome). The patient was 
treated with antihypertensive drugs and diazepam with ben-
efit. A brain MRI performed 10 days later showed partial 
resolution of radiological findings, which were no more 
detectable on a new MRI one month later. Prednisone was 
tapered further, and azathioprine was added as steroid spar-
ing drug. He did not show any other symptom of PRES 
afterward.
Results
Only eight cases of PRES in patients with ANCA-associ-
ated vasculitis have been reported in the literature (Table 1). 
Seven of these are isolated case reports. One has been 
included in a larger review of 18 cases of PRES associated 
with connective tissue diseases [3]. Among the 9 cases of 
PRES linked to ANCA-associated vasculitis reported to 
date (including ours), 3 were males and 6 were females, 
with a mean age of 47.7 years (range 14–77 y.o.). In all 
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cases, the diagnosis of PRES was made on the basis of 
MRI findings. Six patients presented with severe systemic 
hypertension, one with moderate systemic hypertension, 
and two with normal blood pressure. Three patients had an 
underlying diagnosis of granulomatosis with polyangiitis 
(GPA), 2 patients had microscopic polyangiitis (MPA), 3 
had an ANCA-associated vasculitis (namely p-ANCA) with 
no sufficient criteria to make a diagnosis of EGPA, GPA, 
or MPA, and our patient was the only one with a definite 
diagnosis of EGPA. Serum creatinine value was increased 
in 4 patients. In all cases, PRES was diagnosed by the typi-
cal findings of high-signal intensity areas on T2-weighted 
fluid-attenuated inversion-recovery images (FLAIR) and 
low signal intensity on T1-weighted images in the same 
lesions. Eight of nine patients were taking corticosteroids 
at the onset of symptoms of PRES. Three of them were also 
receiving cyclophosphamide (CY) because of the severity 
of the disease. None of them stopped the steroid treatment, 
and only one patient stopped CY. In 4 patients, a methyl-
prednisolone pulse therapy was started, as PRES was con-
sidered a manifestation of the underlying immunologic 
disease. In one case, the diagnosis of PRES preceded the 
diagnosis of the ANCA-associated vasculitis; hence, PRES 
was the first manifestation of the disease. In our case, a 
control MRI 10 days after the onset of symptoms showed 
a significant improvement in the radiological findings, and 
repeated MRI 1 month after the initial severely abnormal 
study showed a complete resolution of the affected areas 
and the patient had a full neurological recovery.
Discussion
PRES is a clinical and radiological entity described for the 
first time by Hinchey et al. [4]. The main clinical symptoms 
and signs are headache, decreased alertness, and behav-
ior ranging from drowsiness to stupor, seizures, vomit-
ing, mental abnormalities including confusion, diminished 
Fig. 1  Bilateral high-intensity areas in the white matter of the occipi-
tal and parietal lobes in MRI T2-weighted image. These findings 
were suggestive of PRES
Table 1  Main features of the nine cases reviewed
GPA granulomatosis with polyangiitis, EGPA eosinophilic granulomatosis with polyangiitis, MPA microscopic polyangiitis, p-ANCA ass. vasc. 
P-ANCA-associated vasculitis with no sufficient criteria to make a diagnosis of GPA, MPA, EGPA, mPSL methylprednisolone, PSL predniso-
lone, PE plasma exchange, CY cyclophosphamide
References Age/sex Underlying disease Medications PRES treatment Blood pressure Creatinine
Primavera [7] 23 M GPA mPSLpulse/CY CY withdrawn 200/150 mmHg 3.6 mg/dl
Kawano [18] 73 F MPA mPSLpulse mPSLpulse 200/100 mmHg 0.9 mg/dl
Kawano [18] 77 F MPA mPSLpulse mPSLpulse 180/120 mmHg 3 mg/dl
Ohta [8] 14 F GPA PSL + PE + CY (with-
drawn at 6 wks because 
of leucopenia)
No changes 180/90 mmHg 7.8 mg/dl
Tajima [12] 76 F p-ANCA ass. vasc. PSL mPSLpulse 130/80 mmHg 0.8 mg/dl
Nishio [16] 15 F GPA PSL- mPSLpulse- CY mPSLpulse-CY 120/60 mmHg 0.27 mg/dl
Fuentes [11] 72 F GPA (?) p-ANCA ass. 
vasc.
PSL PSL only 150/100 mmHg n.a.
Patel [10] 40 M p-ANCA Hemodialysis, mPSL 
pulses + PSL
Dialysis, mPSL- PSL 160/90 mmHg 24.48 mg/dl
Marra Barilaro 
(2014)
40 M EGPA mPSL e PSL PSL only 140/90 mmHg 0.7 mg/dl
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spontaneity and speech, and abnormalities of visual per-
ception like visual loss, including cortical blindness. The 
onset is usually subacute but may be heralded by a seizure. 
Seizures are common at the onset of neurologic symptoms 
but can also develop later. Seizures may begin focally but 
usually become generalized. Multiple seizures are more 
common than single events. Stupor and frank coma may 
develop, but usually patients remain responsive to stimuli 
[5].
The most common abnormality on neuroimaging is 
vasogenic edema involving the white matter in the poste-
rior portions of the cerebral hemispheres, especially in the 
temporo-parieto–occipital regions, bilaterally. However, 
involvement of additional areas of the brain has also been 
reported. Computed tomography findings consist of bilat-
erally symmetric low attenuation in the posterior parietal/
occipital lobes. MRI, particularly diffusion-weighted MRI, 
is the most appropriate radiologic exam and may help in 
discriminating the vasogenic edema of PRES from the 
cytotoxic edema of early cerebral infarction [6]. Typi-
cally vasogenic edema is represented by hyperintensity in 
fluid-attenuated inversion-recovery and T2-weighted MRI, 
while DWI sequences are normal, and the apparent diffu-
sion coefficient map shows increased activity, the exact 
opposite to what would be expected in brain stroke. This 
is a really important feature in differentiating the two con-
ditions. Although posterior changes are prominent in this 
syndrome, frontal involvement is more frequent than poste-
rior on FLAIR imaging and DWI.
The exact pathogenesis of the posterior reversible 
encephalopathy syndrome is not perfectly known. It is 
associated with many conditions causing hypertensive 
encephalopathy, as eclampsia, drug-induced hypertension, 
and renal insufficiency. PRES has also been reported in 
association with many rheumatologic diseases.
Rheumatologic diseases can have varied clinical presen-
tations involving the central nervous system. SLE has been 
the first autoimmune disease linked to PRES [7], but, since 
then, several case reports described the association between 
PRES and Takayasu arteritis, systemic sclerosis, polyarteri-
tis nodosa, Henoch–Schönlein purpura, and granulomatosis 
with polyangiitis.
The differential diagnosis includes multiple embolic 
lesions and vertebrobasilar thrombo-occlusive disease, but 
also widespread inflammatory diseases with involvement 
of the central nervous system (CNS) such as neuro-SLE 
and primary angiitis of the CNS. Patients with PRES and 
patients with CNS vasculitis may have a similar clinical 
presentation characterized by encephalopathy, visual loss, 
seizures, and headache. However, CNS vasculitis lacks the 
typical MRI findings of PRES, which is helpful in distin-
guishing the first condition that might require aggressive 
immunosuppressive therapy from the second that does not.
A possible explanation of this phenomenon is the 
endothelial injury caused by an inflammatory state, vascu-
litis, or anti-endothelial antibodies that could contribute to 
the disruption of the blood–brain barrier and lead to cer-
ebral vasogenic edema. In particular, in ANCA-associated 
vasculitides, ANCA could by itself activate neutrophils 
causing the endothelial cell injury, leading to the develop-
ment of PRES [8]. This can also explain the efficacy of 
strong immunosuppressive therapy as treatment of PRES 
in patients with ANCA-associated vasculitis [3]. How-
ever, endothelial injury alone is likely not sufficient to 
cause PRES and a second factor, namely hypertension, 
can lead to alterations in cerebral blood flow regulation. In 
particular, hypertension causes increased capillary filtra-
tion, and sudden elevations in systemic blood pressure can 
exceed the autoregulatory capacity of the brain vascula-
ture. Regions of vasodilation and vasoconstriction develop, 
especially in arterial boundary zones, and there is a break-
down of the blood–brain barrier with focal transudation of 
fluid and petechial hemorrhages. Hence it is likely that at 
least two mechanisms are involved in the development of 
PRES, namely hypertension and endothelial injury, both 
leading to altered cerebral autoregulation. [9].
Only in one case of the 9 reported so far (Table 1), 
PRES was the onset manifestation of the undergoing vas-
culitis [10] (the involvement of CNS in ANCA-associated 
vasculitides is rare). All remaining patients had a previ-
ous diagnosis of ANCA-associated vasculitis and were 
under steroid treatment at the onset of PRES. In particular, 
five patients were treated with methylprednisolone pulse 
therapy, in two cases associated with cyclophosphamide, 
one patient with oral methylprednisolone and cyclophos-
phamide [3], and two with oral methylprednisolone alone 
[11, 12]. Remarkably, no patient stopped the corticosteroid 
therapy after the onset of PRES, even those who presented 
with severe hypertension. In four patients, PRES was suc-
cessfully treated with methylprednisolone pulse therapy, 
supporting the hypothesis of PRES as a neurologic mani-
festation of the underlying rheumatologic disease.
Immunomodulatory drugs have also been associated 
with the development of PRES. The pathophysiology of 
this phenomenon is not completely understood, but it can 
be explained by a direct effect on the cerebral vasculature 
causing a capillary leak leading to the cerebral vasogenic 
edema. Another possible mechanism is vasoconstriction 
caused by overproduction of endothelin. Drugs most fre-
quently associated with PRES are the calcineurin inhibi-
tors, cyclosporine, and tacrolimus [13]. However, cases 
of PRES have also been described in association with 
mycophenolate mofetil, methotrexate [14], and etaner-
cept [15]. Corticosteroids represent the first-line therapy 
in ANCA-associated vasculitides. All patients reviewed 
in this article, except one, received steroid treatment 
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before presenting PRES. This effect can be explained 
by an increase in systemic blood pressure caused by 
CS. Moreover, corticosteroid therapy has been shown to 
inhibit endothelial prostacyclin production and to increase 
thromboxane A2 production, leading to platelet aggre-
gation and to a decrease in blood flow to the organs. A 
decreased blood flow in the kidney activates the renin-
angiotensin system leading to a rapid elevation in blood 
pressure and precipitating endothelial dysfunction [16]. It 
is likely that in our patient steroid therapy, increasing the 
blood pressure could have worked as a trigger in a predis-
posed substrate represented by the endothelial injury due 
to the vasculitis.
The treatment of PRES is mainly based on reducing 
blood pressure. Antiepileptic drugs should be used to con-
trol acute seizures. Most case series suggest the PRES is 
usually a benign condition, but neurologic sequelae have 
been reported with evolution of the initial vasogenic edema 
into cytotoxic edema, infarction, or hemorrhage [17]. 
However, complete resolution of neurological symptoms 
along with improvement or resolution of imaging altera-
tions occurs within few days to weeks of presentation, if a 
prompt control of blood pressure is started along with the 
removal of inciting factors.
In our case, the patient was under oral prednisone at 
PRES onset. We decided not to stop or modify the ster-
oid therapy and started aggressive blood pressure control 
with carvedilol and clonidine. We also started intravenous 
diazepam as antiepileptic therapy. However, other authors, 
as Kawano and Nishio [18], [16], considered PRES as a 
neurologic complication of the underlying vasculitis and 
promptly started methylprednisolone intravenous pulse 
therapy.
In ANCA-associated vasculitides, as other autoimmune 
diseases, patients presenting with symptoms of PRES and 
major organ involvement represent a challenge to treatment 
with immunosuppressive medications, especially consider-
ing that some of these therapies have been associated with 
the development of PRES. However, since an inflammatory 
process might be implicated, judicious use of these agents 
along with aggressive blood pressure control and support-
ive therapy may contribute to the resolution of the encepha-
lopathic syndrome providing at the same time adequate 
control of other organs involvement. In conclusion, phy-
sicians should be aware that immunosuppressive therapy 
can be a trigger of PRES, but, especially in severe cases 
where the immunologic disease is life threatening, stopping 
immunosuppression is not advisable. Larger clinical stud-
ies, made difficult by the rarity of both conditions, are war-
ranted to optimize the management of vasculitis-associated 
PRES.
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